Holyoake TL - Search Results

1

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Karvela M, Helgason GV, Holyoake TL. Karvela M, et al. Among authors: holyoake tl. Expert Rev Anticancer Ther. 2012 Mar;12(3):381-92. doi: 10.1586/era.12.10. Expert Rev Anticancer Ther. 2012. PMID: 22369329 Review.

2

Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?

Drummond MW, Holyoake TL. Drummond MW, et al. Among authors: holyoake tl. Blood Rev. 2001 Jun;15(2):85-95. doi: 10.1054/blre.2001.0152. Blood Rev. 2001. PMID: 11409908 Review.

3

A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.

Jørgensen HG, Holyoake TL. Jørgensen HG, et al. Among authors: holyoake tl. Hematol Oncol. 2001 Sep;19(3):89-106. doi: 10.1002/hon.667. Hematol Oncol. 2001. PMID: 11574931 Review.

4

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

Jørgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. Jørgensen HG, et al. Among authors: holyoake tl. Blood. 2002 Jan 15;99(2):713-5. doi: 10.1182/blood.v99.2.713. Blood. 2002. PMID: 11781261 Free article.

5

Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia.

Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Holyoake TL, et al. Leukemia. 2002 Apr;16(4):549-58. doi: 10.1038/sj.leu.2402444. Leukemia. 2002. PMID: 11960331 Review.

6

Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.

Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A; United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. Drummond MW, et al. Among authors: holyoake tl. Br J Haematol. 2003 Nov;123(3):479-83. doi: 10.1046/j.1365-2141.2003.04599.x. Br J Haematol. 2003. PMID: 14617010 Free article.

7

Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.

Drummond M, Lennard A, Brûmmendorf T, Holyoake T. Drummond M, et al. Leuk Lymphoma. 2004 Sep;45(9):1775-81. doi: 10.1080/10428190410001693542. Leuk Lymphoma. 2004. PMID: 15223635

8

Evolving molecular therapy for chronic myeloid leukaemia--are we on target?

Copland M, Jørgensen HG, Holyoake TL. Copland M, et al. Among authors: holyoake tl. Hematology. 2005 Oct;10(5):349-59. doi: 10.1080/10245330500234195. Hematology. 2005. PMID: 16203604 Review.

9

Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.

Jørgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, Holyoake TL. Jørgensen HG, et al. Among authors: holyoake tl. Clin Cancer Res. 2006 Jan 15;12(2):626-33. doi: 10.1158/1078-0432.CCR-05-0429. Clin Cancer Res. 2006. PMID: 16428509

10

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N, Barow M, Mountford JC, Holyoake TL. Copland M, et al. Among authors: holyoake tl. Blood. 2006 Jun 1;107(11):4532-9. doi: 10.1182/blood-2005-07-2947. Epub 2006 Feb 9. Blood. 2006. PMID: 16469872 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

216 results

Search Page